Thorough QT/QTc Study to Evaluate the Effects of Ecopipam (EBS-101) on Cardiac Repolarization

Inclusion Criteria: * Male or female of nonchildbearing potential * 18 to 55 years of age * BMI of 18 to 30 kg/m2, and weight of at least 50 kg for males and 45 kg for females. * Subject considered by the investigator to be in good general health as determined by medical history, clinical laboratory test results, vital sign measurements, 12-lead ECG results, and PE findings. * Male subjects with female partners of childbearing potential must agree to use a double-barrier method of contraception during the study and agree to continue the use of male contraception for at least 90 days after the last dose of study drug. * Male subjects must be willing to refrain from donating sperm during study participation and for 90 days after the last dose of study drug. * The subject is able to provide written informed consent and agrees to comply with all protocol requirements. Exclusion Criteria: * Female subjects of childbearing potential or who are currently pregnant or lactating * Subjects with a history of significant medical illness * Clinically significant abnormalities on screening tests/exams * History of or serious risk of committing suicide * Donation of plasma within 7 days prior to dosing * Donation of significant loss of blood within 30 days prior to dosing * Major surgery within 3 months or minor surgery within 1 month prior to CRU admission * Use of prohibited prescription, over-the-counter medications or natural health products * Alcohol-based products within 24 hours p…